Urology
Articles filed under Urology.
NICE recommends sunitinib (Sutent) for the first-line treatment of metastatic renal cancer
NICE (UK) recommends the tyrosine kinase inhibitor sunitinib (Sutent) first line treatment of metastatic renal cell carcinoma. Implications for patients that are on immunotherapy
Animation on the mechanism of action of GnRH agonists and antagonists in the treatment of prostate cancer
The video animations below depict the mechanism of action of GnRH agonists and antagonists in the treatment of prostate cancer. The three movies will start playing at the same time, you can right-click on each of them and deselect “play” in case you want to stop any of them. This excerpt from the Wikipedia article
Degarelix (Firmagon) for prostate cancer: now approved by FDA
Related to EMEA’s positive opinion on degarelix (Firmagon) for prostate cancer, FDA issues this press release dated Dec. 29, 2008: FDA Approves Drug for Patients with Advanced Prostate Cancer The U.S. Food and Drug Administration recently approved the injectable drug degarelix, the first new drug in several years for prostate cancer.
Temsirolimus (Torisel): kinase inhibitor for the treatment of advanced renal cell carcinoma. Australian Prescriber review
From Australian Prescriber: Temsirolimus Torisel (Wyeth) vials containing 25 mg/mL concentrate Approved indication: advanced renal cell carcinoma Australian Medicines Handbook section 14.2.3 About 30% of patients with renal cell carcinoma have advanced or metastatic disease at the time of diagnosis. Chemotherapy is generally ineffective and nephrectomy is the mainstay of treatment for disease confined to
Alfuzosin does not improve symptoms of chronic prostatitis- chronic pelvic pain syndrome
From JournalWatch: Alpha-Blocker Does Not Ease Symptoms of Chronic Prostatitis Alfuzosin, an alpha-adrenergic–receptor blocker, does not improve symptoms in men with chronic prostatitis–chronic pelvic pain syndrome, according to a New England Journal of Medicine study.
EMEA press release: CHMP positive opinion about degarelix (Firmagon) for prostate cancer
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE SUMMARY OF POSITIVE OPINION for FIRMAGON International Nonproprietary Name (INN): degarelix (as acetate) On 18 December 2008 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending to grant a marketing authorisation for the medicinal product Firmagon, 80 mg and 120 mg, powder and
Alpha 1 adrenergic receptors antagonists (blockers): mechanism of action animation
Additional information about alpha 1 blocking drugs. Source: Bertram G. Katzung, Basic & Clinical Pharmacology (Mc Graw-Hill Medical, 2007) ” Phentolamine, an imidazoline derivative, is a potent competitive antagonist at both alpha 1 and alpha 2 receptors . Phentolamine causes a reduction in peripheral resistance through blockade of alpha 1 receptors and possibly alpha 2
EMEA: Norfloxacin should not be used to treat acute or chronic complicated pyelonephritis
This press release was published on July 2008: EMEA recommends restricted use of oral norfloxacin-containing medicines in urinary infections The European Medicines Agency has recommended restricting the use of oral norfloxacin-containing medicines in urinary infections. The Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded that the marketing authorisations for oral norfloxacin-containing medicines,
Drugs acting on the autonomic nervous system: animation showing their mechanism of action
The following is a list of drugs related to the animation: Adrenoceptor-Activating & Other Sympathomimetic Drugs Dobutamine, Ephedrine, Epinephrine, Hydroxyamphetamine, Isoproterenol, Methylphenidate, Naphazoline, Norepinephrine. Adrenoceptor Antagonist Drugs Acebutolol, Atenolol, Betaxolol, Bisoprolol, Carteolol, Carvedilo,l Carvedilol, Esmolol, Labetalol, Metoprolol, Nadolol, Pindolol, Propranolol, Sotalol, Timolol. Cholinoceptor-Activating (Acetylcholine receptor stimulants) Acetylcholine, Bethanechol, Carbachol, Cevimeline, Pilocarpine. Cholinoceptor-Blocking Drugs (Cholinoceptor antagonists)
Toviaz (fesoterodine fumarate): new drug to treat overactive bladder
FDA press release about the approval of Toviaz (fesoterodine fumarate): The U.S. Food and Drug Administration has approved a new drug to help patients suffering from overactive bladder (OAB). Toviaz (fesoterodine fumarate) works by relaxing the smooth muscle tissue of the bladder, thus reducing the urinary frequency, urge to urinate, and sudden urinary incontinence (leakage